Please ensure Javascript is enabled for purposes of website accessibility

Exact Sciences Falls in After-Hours Trading on Q4 Results

By Eric Volkman - Feb 16, 2021 at 9:22PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Due to an accounting charge taken because of an acquisition, the company was deep in the red on the bottom line.

Exact Sciences (EXAS -1.54%) released its results for the fourth quarter of 2020 after market close on Tuesday. Investors indicated their displeasure by trading the stock down.

For the period, the healthcare diagnostics specialist posted just over $466 million in revenue, which was nearly 58% higher on a year-over-year basis.

On a less encouraging note, it flipped to a net loss of almost $437 million ($2.79 per share) on the bottom line. However, this was heavily affected by a nearly $413 research and development charge the company booked due to the acquisition of cancer diagnostics developer Base Genomics. In Q4 2019, Exact Sciences' net income was almost $78 million.

Doctor writing on a patient's medical chart.

Image source: Getty Images.

On average, analysts were expecting $446 million on the top line, but a per-share net loss of only $0.22. Some net loss estimates might not have factored in such a heavy R&D charge from the Base Genomics deal.

Exact Sciences' revenue growth has been fueled by both its cancer diagnostics and its coronavirus testing products. As the pandemic (hopefully) subsides, the company is counting on the former category to drive growth.

"We are a leader in cancer diagnostics because of our people, scientific platform, and market-leading Cologuard and Oncotype tests," CEO Kevin Conroy said. "We aim to extend this leadership throughout the cancer continuum and bring additional tests to patients to help improve cancer outcomes."

Investors might not be buying Conroy's line. The stock was down by 4.4% in post-market trading, which compared unfavorably to the slight decline of the S&P 500 index during regular hours.

 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Exact Sciences Corporation Stock Quote
Exact Sciences Corporation
EXAS
$53.17 (-1.54%) $0.83

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
330%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/22/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.